Ylöstalo P, Granberg S, Bäckström A C, Hirsjärvi-Lahti T
Department of Obstetrics and Gynaecology, Helsinki University Central Hospital, Finland.
Maturitas. 1996 Apr;23(3):313-7. doi: 10.1016/0378-5122(96)00993-0.
To evaluate the effect of hormone replacement treatment (HRT) with percutaneous estradiol and cyclical peroral medroxyprogesterone acetate (MPA) every month or every third month on the uterus and endometrium of postmenopausal women.
Uterine size and endometrial thickness were measured by transvaginal sonography in 159 postmenopausal women before HRT, and after 6 and 12 months on HRT during 9-12 days of the MPA administration periods.
During HRT, uterine size and endometrial thickness increased. The percentage increase in uterine diameter varied between 3.8% and 19.6%, and endometrial thickness varied between 28.7% and 76.4%, being greater in the group receiving MPA every third month than in the groups receiving MPA every month. Myomas grew during the first 6 months on HRT but increased no further during the next 6 months on HRT.
The increases in uterine size, myomas and endometrial thickness during HRT were moderate and not problematic and occurred mainly during the first 6 months on HRT.
评估经皮雌二醇与每月或每三个月周期性口服醋酸甲羟孕酮（MPA）进行激素替代治疗（HRT）对绝经后女性子宫和子宫内膜的影响。
对159名绝经后女性在HRT前、HRT 6个月和12个月且处于MPA给药期的第9 - 12天时，通过经阴道超声测量子宫大小和子宫内膜厚度。
在HRT期间，子宫大小和子宫内膜厚度增加。子宫直径增加百分比在3.8%至19.6%之间，子宫内膜厚度增加百分比在28.7%至76.4%之间，每三个月接受一次MPA治疗的组比每月接受一次MPA治疗的组增加幅度更大。子宫肌瘤在HRT的前6个月生长，但在接下来的6个月HRT期间不再进一步增大。
HRT期间子宫大小、子宫肌瘤和子宫内膜厚度的增加幅度适中且无问题，主要发生在HRT的前6个月。
